graph) and the increased spend 
compared to 2022. Intangible assets under construction for a 
net worth of EUR 9.0 million which includes 
development costs related to Product 
Lifecycle Management and the EU Medical 
Device Regulation. In accordance with the Royal Decree of 
December 15, 2015, research costs have been 
capitalized and amortized over the year since 
January 1, 2016. Development costs in 2023 
were, as mentioned before, as from 2023 
onwards depreciated monthly on a pro rata 
temporis basis (36 months). For research costs 
all expenditure was depreciated within the year.